Physician, researcher, advocate for the notion that an ounce of data is worth a thousand pounds of opinion
Views here surely my own
Professor, Dean @Brown_SPH
Pooled analysis of 4 Oxford/AZ trials out @TheLancet
Among vaccinated, still no hospitalizations/deaths from COVID
Modeling suggests that waiting 90 days for 2nd dose improves protection
Findings support UK's first dose first approach
Delaying the 2nd dose of the AZ/Oxford vaccine may elicit better protection and antibody responses, with similar protection between doses.
So the UK policy may not be a tradeoff between individual and population benefit, at least for the AZ/Oxford vaccine. 1/ twitter.com/ashishkjha/sta…
When evidence emerges to support one hypothesis it doesn’t mean all your hypotheses are correct.
We should adjust vaccine dosing when we have sufficient scientific evidence to support it, not before.
Vaccine hesitant folks are generally dissuaded by cavalier approaches. twitter.com/ashishkjha/sta…
I like this report much better than the study of Pfizer vaccine in Israel that got lots of hype today.
Why? This one examined efficacy for longer period of time, & shows that a delayed booster is not just safe, but HELPFUL.
(Still have q's about AZ's studies, though...!) twitter.com/EricTopol/stat…
And re Pfizer vaccine --> the Israeli study didn't tell us anything we didn't already know from clinical trials. Unanswered q's: how strong is the reaction? Does the booster lengthen immunogenicity? Does it STRENGTHEN immunogenicity (e.g., against variants)? Lots to know, still!
NEW—Post-hoc exploratory analyses suggest 3-month interval between doses of Oxford #COVID19 #vaccine results in higher efficacy than 6-week interval, with first dose offering 76% protection in the 3 months between doses. hubs.li/H0GVc0G0pic.twitter.com/S3V07aV8Ri
@TheLancet Sounds worth a read. However post hoc is not the only problem with data of this sort. It’s not just the analysis that was not prespecified but what happened in the trial. @"Dilly-Dally Delay?"linkedin.com/pulse/dilly-da…
Virologist.Likes history, hiking & a good movie.Favourite viruses? Coronavirus,Emerging & Oncogenic Viruses. Job seeker.Favourite country? UK. Dad. Bibliophile.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials thelancet.com/journals/lance…
New in @TheLancet> Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of #ChAdOx1 nCoV-19 (#AZD1222) #vaccine: a pooled analysis of four randomised trials #COVID19 thelancet.com/journals/lance…
“Exploratory analyses show that higher vaccine efficacy is obtained with a longer prime-boost interval, and that a single dose of vaccine is efficacious in the first 90 days, providing further evidence for current policy” twitter.com/lancetmicrobe/…
Pooled analysis of 4 RCTs shows higher efficacy when the Oxford-AZ vaccine doses were spaced 12 weeks apart than 6 weeks apart. Posthoc analysis, but compelling nevertheless given the magnitude of difference 81% vs 55%
Epidemiologist and biostatistician, Neue Deutsche Härte fan, avid reader of sci-fi, contrarian. Working for #ZeroCOVID.
Opinions my own. Blog: https://t.co/v0oKkyfhjf
Further AZ results are published. The most important endpoint is essentially unchanged. Efficacy against symptomatic infection (2 standard doses) is 63%.
Post-hoc analyses suggest increased efficacy with a larger dose interval.
6 wk: 55%
>=12 wk: 81%